Human stool (IBD patients, LC-MS/MS)

Fecal samples (n=52) of a cohort of IBD patients were collected before and after 14 weeks of treatment with three different biologics. Clinical disease activity scores were used to determine the clinical response and remission. Fecal metaproteomes of remitting patients (n=12) and of non-remitting patients (n=12) were compared before treatment and changes within both groups were assessed over sampling time to identify functional changes and potential human and microbial biomarkers. (2 patients were excluded from finala analyses as the started the therapy in a remitting disease state.)